GSK Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

GSK şirketinin kazançları yıllık ortalama -5.2% oranında azalırken, Pharmaceuticals sektörünün kazançları yıllık 5.2% oranında azalan oldu. Gelirler yıllık ortalama 1.8% oranında azalan oldu. GSK şirketinin öz sermaye getirisi 21.2% olup, net marjı 8% dir.

Anahtar bilgiler

-5.2%

Kazanç büyüme oranı

-5.8%

EPS büyüme oranı

Pharmaceuticals Sektör Büyümesi	14.1%
Gelir büyüme oranı	-1.8%
Özkaynak getirisi	21.2%
Net Marj	8.0%
Son Kazanç Güncellemesi	30 Sep 2024

Yakın geçmiş performans güncellemeleri

GSK's (LON:GSK) Conservative Accounting Might Explain Soft Earnings

Nov 06

Recent updates

We Think Shareholders Are Less Likely To Approve A Large Pay Rise For GSK plc's (LON:GSK) CEO For Now

May 02

These 4 Measures Indicate That GSK (LON:GSK) Is Using Debt Reasonably Well

Apr 19

Gelir ve Gider Dağılımı

GSK nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.

Kazanç ve Gelir Geçmişi

LSE:GSK Gelir, gider ve kazançlar (GBP Millions )
Tarih	Gelir	Kazançlar	G+A Giderleri	Ar-Ge Giderleri
30 Sep 24	31,311	2,511	10,839	6,042
30 Jun 24	31,446	4,033	9,284	6,049
31 Mar 24	30,740	4,484	9,070	5,956
31 Dec 23	30,328	4,928	9,156	5,823
30 Sep 23	29,652	6,078	8,965	5,580
30 Jun 23	29,334	5,373	8,767	5,436
31 Mar 23	29,085	4,455	8,460	5,282
31 Dec 22	29,324	4,461	8,179	5,153
30 Sep 22	29,024	3,387	7,803	4,905
30 Jun 22	27,822	3,505	7,429	4,741
31 Mar 22	26,731	4,013	7,104	4,691
31 Dec 21	24,696	3,316	6,784	4,627
30 Sep 21	26,359	3,567	7,436	4,640
30 Jun 21	28,378	3,934	8,285	4,566
31 Mar 21	30,164	4,983	9,176	4,622
31 Dec 20	24,354	4,873	7,041	4,397
30 Sep 20	34,259	6,371	10,719	4,537
30 Jun 20	34,998	6,679	11,085	4,648
31 Mar 20	35,183	5,380	10,993	4,519
31 Dec 19	33,754	4,645	10,962	4,405
30 Sep 19	33,052	4,561	10,103	4,266
30 Jun 19	31,759	4,427	9,575	4,065
31 Mar 19	31,260	3,904	9,488	3,887
31 Dec 18	30,821	3,623	9,500	3,799
30 Sep 18	30,263	1,862	9,234	3,755
30 Jun 18	30,014	1,656	9,185	3,696
31 Mar 18	30,024	1,035	9,143	3,890
31 Dec 17	30,186	1,532	9,424	3,925
30 Sep 17	30,133	2,335	9,303	3,886
30 Jun 17	29,832	1,931	9,260	3,863
31 Mar 17	29,044	1,676	9,017	3,604
31 Dec 16	27,889	912	8,852	3,550
30 Sep 16	26,589	301	8,553	3,370
30 Jun 16	25,174	31	8,025	3,226
31 Mar 16	24,530	615	8,097	3,163
31 Dec 15	23,923	8,422	9,232	3,560
30 Sep 15	23,823	9,809	7,810	3,218
30 Jun 15	23,342	9,672	7,425	3,227
31 Mar 15	23,015	10,177	7,261	3,258
31 Dec 14	23,006	2,756	8,246	3,450
30 Sep 14	23,726	4,184	7,209	3,333
30 Jun 14	24,590	4,752	7,673	3,359
31 Mar 14	25,647	5,143	7,820	3,478
31 Dec 13	26,505	5,436	8,480	3,923

Kaliteli Kazançlar: GSK büyük bir tek seferlik zarar ile £3.0B, 30th September, 2024 tarihine ait son 12 aylık mali sonuçları etkiliyor.

Büyüyen Kar Marjı: GSK 'nin mevcut net kar marjları (8%) geçen yılın (20.5%) değerinden daha düşüktür.

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: GSK şirketinin kazançları son 5 yılda yılda 5.2% oranında azaldı.

Büyüme Hızlandırma: GSK 'in son bir yıldır negatif kazanç büyümesi oldu, bu nedenle 5 yıllık ortalamasıyla karşılaştırılamaz.

Kazançlar vs. Sektör: GSK geçtiğimiz yıl negatif kazanç büyümesine ( -58.7% ) sahipti ve bu da onu Pharmaceuticals sektör ortalamasıyla ( 4.5% ) karşılaştırmayı zorlaştırıyordu.

Özkaynak Getirisi

Yüksek ROE: GSK 'nin Özsermaye Getirisi ( 21.17% ) yüksek olsa da, bu ölçüm yüksek borç seviyeleri nedeniyle çarpıktır.

GSK Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Anahtar bilgiler

Yakın geçmiş performans güncellemeleri

GSK's (LON:GSK) Conservative Accounting Might Explain Soft Earnings

Third quarter 2024 earnings: EPS misses analyst expectations

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

GSK plc to Report Q2, 2024 Results on Jul 31, 2024

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Recent updates

GSK's (LON:GSK) Conservative Accounting Might Explain Soft Earnings

GSK plc (LON:GSK) Not Flying Under The Radar

GSK (LON:GSK) Is Paying Out A Dividend Of £0.15

Third quarter 2024 earnings: EPS misses analyst expectations

Consensus EPS estimates fall by 15%

GSK plc Announces New Positive Arexvy Data in Younger Adults At Risk

GSK plc Announces US Food and Drug Administration Accepts New Drug Application for Treatment of Uncomplicated Urinary Tract Infections in Female Adults and Adolescents

GSK plc Announces Positive Headline Results from the Phase III Clinical Trials ANCHOR-1 and ANCHOR-2

Roche/Genentech's Gazyva Poised to Transform Lupus Nephritis Treatment After Positive Phase III Results

GSK plc Presents Positive Data for Arexvy, its Respiratory Syncytial Virus Vaccine

Gsk Plc's Menveomeningococcal Vaccine in New Single-Vial, Fully Liquid Presentation Receives Positive European Chmp Opinion

GSK plc Reaches Two Confidential Settlements in Cases Filed in California State Court with John Russell

GSK plc Announces Positive Topline Data on Co-Administration of AREXVY and SHINGRIX

GSK plc Announces Positive Headline Results of A Phase Ii Trial (Nct06431607) for Its Mrna Seasonal Influenza Vaccine Programme

GSK plc Reaches Confidential Settlement in Zantac Litigation with Isaac Dixon

GSK plc Provides Update on Phase I/II Therapeutic Herpes Simplex Virus Vaccine Trial

Does GSK (LON:GSK) Have A Healthy Balance Sheet?

GSK plc Announces European Commission Has Authorised Arexvy for Active Immunisation for the Prevention of Lower Respiratory Tract Disease

GSK plc Announces Zantac (Ranitidine) Litigation Update

GSK plc Receives US Food and Drug Administration Breakthrough Therapy Designation for GSK5764227

Gsk plc Announces Zantac (Ranitidine) Litigation Update

GSK plc Announces Zantac (Ranitidine) Litigation Update

GSK (LON:GSK) Is Paying Out A Dividend Of £0.15

Second quarter dividend of UK£0.15 announced

GSK plc Announces US FDA Expands Jemperli (Dostarlimab-Gxly) Plus Chemotherapy Approval to All Adult Patients with Primary Advanced or Recurrent Endometrial Cancer as the First and Only Immuno-Oncology-Based Treatment to Show an Overall Survival Benefit

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

GSK plc Declares Second Interim Dividend for Second Quarter of 2024, Payable on 10 October 2024

GSK plc Announces Blenrep EMA Filing Acceptance

GSK plc Begins Shipping Influenza Vaccine Doses for 2024-25 Season

GSK's Omjjara (Momelotinib) Receives Approval in Japan for Treatment of Myelofibrosis

iTeos Therapeutics, Inc. and GSK Initiate GALAXIES Lung-301 Phase 3 Study, Assessing Belrestotug and Dostarlimab in Previously Unresectable Locally Advanced / Metastatic PD-L1 Selected Non-Small Cell Lung Cancer

GSK plc Announces That the US Food and Drug Administration (FDA) Has Approved Arexvy

GSK plc (LSE:GSK) acquired Elsie Biotechnologies for $50 million.

GSK plc Announces Positive Results from an Interim Analysis of the DREAMM-8 Phase III Head-To-Head Trial Evaluating Belantamab Mafodotin

GSK plc Provides Litigation Update

An unknown buyer intended to acquire 4.2% stake in Haleon plc (LSE:HLN) from GSK plc (LSE:GSK) for £1.2 billion.

GSK Announces Intention to Sell Approximately 385 Million Shares in Haleon

Gsk plc Announces Board Committee Changes

GSK (LON:GSK) Will Pay A Dividend Of £0.15

First quarter dividend of UK£0.15 announced

GSK plc to Report Q2, 2024 Results on Jul 31, 2024

We Think Shareholders Are Less Likely To Approve A Large Pay Rise For GSK plc's (LON:GSK) CEO For Now

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

GSK plc Announces the US Food and Drug Administration Accepted the Supplemental Biologics License Application for Jemperli

These 4 Measures Indicate That GSK (LON:GSK) Is Using Debt Reasonably Well

GSK plc Announces Positive Results from the Pivotal Eagle-1 Phase III Trial for Gepotidacin

GSK plc Announces US Food and Drug Administration Accepts for Review Biologics License Application for its 5-in-1 Meningococcal ABCWY (MenABCWY) Vaccine Candidate

GSK plc, Annual General Meeting, May 08, 2024

GSK plc Appoints Hal Dietz as Member of Nominations & Corporate Governance Committee, Effective 11 March 2024

Gelir ve Gider Dağılımı

Kazanç ve Gelir Geçmişi

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Özkaynak Getirisi

Varlık Getirisi

Kullanılan Sermaye Getirisi

Geçmişte güçlü performans gösteren şirketleri keşfedin